CA3039177A1 - Antibodies with improved stability to intestinal digestion - Google Patents

Antibodies with improved stability to intestinal digestion Download PDF

Info

Publication number
CA3039177A1
CA3039177A1 CA3039177A CA3039177A CA3039177A1 CA 3039177 A1 CA3039177 A1 CA 3039177A1 CA 3039177 A CA3039177 A CA 3039177A CA 3039177 A CA3039177 A CA 3039177A CA 3039177 A1 CA3039177 A1 CA 3039177A1
Authority
CA
Canada
Prior art keywords
antibody
bovine
antibodies
igg1
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3039177A
Other languages
English (en)
French (fr)
Inventor
Randall Edward Burton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Circle33 LLC
Original Assignee
Circle33 LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Circle33 LLC filed Critical Circle33 LLC
Publication of CA3039177A1 publication Critical patent/CA3039177A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3039177A 2015-10-05 2016-09-29 Antibodies with improved stability to intestinal digestion Pending CA3039177A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562237270P 2015-10-05 2015-10-05
US62/237,270 2015-10-05
PCT/US2016/054304 WO2017062253A2 (en) 2015-10-05 2016-09-29 Antibodies with improved stability to intestinal digestion

Publications (1)

Publication Number Publication Date
CA3039177A1 true CA3039177A1 (en) 2017-04-13

Family

ID=58488349

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3039177A Pending CA3039177A1 (en) 2015-10-05 2016-09-29 Antibodies with improved stability to intestinal digestion

Country Status (8)

Country Link
US (2) US11891440B2 (https=)
EP (1) EP3359190A4 (https=)
JP (2) JP7235287B2 (https=)
AU (2) AU2016335912B2 (https=)
BR (1) BR112018006953A2 (https=)
CA (1) CA3039177A1 (https=)
IL (1) IL258496A (https=)
WO (1) WO2017062253A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6960634B2 (ja) * 2016-08-15 2021-11-05 国立大学法人北海道大学 抗ｐｄ−ｌ１抗体
WO2020123798A1 (en) * 2018-12-12 2020-06-18 President And Fellows Of Harvard College Bovine versions of fcmbl for the detection and treatment of bovine microbial infections
US20230416410A1 (en) * 2020-11-20 2023-12-28 Zoetis Services Llc Bovine antibody variants
EP4695308A1 (en) * 2023-09-14 2026-02-18 Invitrogen BioServices India Private Limited Engineered antibodies and uses thereof
CN120209146A (zh) * 2025-03-31 2025-06-27 上海百英生物科技股份有限公司 一种包含非天然氨基酸修饰的Claudin 6抗体及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP2725035A1 (en) * 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
US8647626B2 (en) * 2007-10-02 2014-02-11 Avaxia Biologics, Incorporated Compositions comprising TNF-specific antibodies for oral delivery
US20120276092A1 (en) * 2009-10-29 2012-11-01 Jinquan Luo Antibody Glycosylation Variants
AR084210A1 (es) 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
US9279161B2 (en) * 2010-12-27 2016-03-08 Japan Health Sciences Foundation Monoclonal antibody recognizing human papillomavirus (HPV) L2 protein and method for measuring HPV-neutralizing antibody titer using the same
WO2013019889A2 (en) * 2011-08-01 2013-02-07 Avaxia Biologics, Inc. Bovine polyclonal antibody specific for human tnf
JP6960635B2 (ja) * 2016-08-15 2021-11-05 国立大学法人北海道大学 抗ｐｄ−１抗体

Also Published As

Publication number Publication date
US20240067715A1 (en) 2024-02-29
US11891440B2 (en) 2024-02-06
AU2016335912A1 (en) 2018-05-24
AU2016335912B2 (en) 2023-08-31
EP3359190A2 (en) 2018-08-15
IL258496A (en) 2018-05-31
AU2023216791A1 (en) 2023-09-07
US20220073602A1 (en) 2022-03-10
EP3359190A4 (en) 2020-05-06
WO2017062253A3 (en) 2017-05-11
JP2018537117A (ja) 2018-12-20
JP2022185053A (ja) 2022-12-13
WO2017062253A2 (en) 2017-04-13
BR112018006953A2 (pt) 2018-10-23
JP7235287B2 (ja) 2023-03-08

Similar Documents

Publication Publication Date Title
US20240067715A1 (en) Antibodies with improved stability to intestinal digestion, polynucleotides thereof and methods of use thereof to treat disease
CN108368510B (zh) 特异性结合人cd40的激动性抗体和使用方法
US11525005B2 (en) Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
NZ719092A (en) Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
CN112969714A (zh) 抗cd40抗体、其抗原结合片段及其医药用途
WO2022105914A1 (zh) Cd70抗体及其应用
TW201942135A (zh) 抗cd27 抗體、其抗原結合片段及其醫藥用途
TW201831512A (zh) Ｔｉｍ－３抗體、其抗原結合片段及醫藥用途
US20250346673A1 (en) Anti-bdca2 antibody and use thereof
TW201900213A (zh) 免疫球蛋白ａ陽性細胞的調節
CN113906053B (zh) 抗cea抗体及其应用
CN112513087A (zh) 抗cd38抗体、其抗原结合片段及医药用途
CN113260632A (zh) 包含IgA抗体构建体的组合物和方法
JP2023076596A (ja) ＴＧＦ－βＲＩＩ結合タンパク質
WO2023103788A1 (zh) 特异性结合肺炎克雷伯菌o2抗原和o1抗原的双特异性抗体以及组合物
WO2022103871A1 (en) Therapeutic compositions for the treatment of covid-19
HK40094429A (en) Tgf-beta-rii binding proteins
HK40051457A (en) Anti-cd40 antibody, antigen binding fragment and pharmaceutical use thereof
HK40059443A (en) Compositions and methods comprising iga antibody constructs

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210916

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250912

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251113

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260107